Phase I Trial of a Novel Anti-HER2 Antibody–Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer

医学 胃肠病学 内科学 肺炎 转移性乳腺癌 乳腺癌 毒性 不利影响 抗体-药物偶联物 癌症 肺癌 药理学 抗体 免疫学 单克隆抗体
作者
Jian Zhang,Dongmei Ji,Weina Shen,Qin Xiao,Yajia Gu,Joyce O’Shaughnessy,Xichun Hu
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:28 (19): 4212-4221 被引量:56
标识
DOI:10.1158/1078-0432.ccr-22-0456
摘要

ARX788 is a novel antibody-drug conjugate (ADC) comprised of an anti-HER2 monoclonal antibody and a potent tubulin inhibitor payload AS269 that is site-specifically conjugated to the antibody via a non-natural amino acid incorporated into the antibody. Herein, we present the results of a phase I study of the safety, pharmacokinetics, and antitumor activity of ARX788 in HER2-positive metastatic breast cancer (MBC) patients.Patients with HER2-positive MBC received ARX788 at doses of 0.33, 0.66, 0.88, 1.1, 1.3, or 1.5 mg/kg Q3W, or 0.88, 1.1, or 1.3 mg/kg Q4W. The dose-limiting toxicity (DLT) was assessed for 84 days for pulmonary toxicity and at a duration of one cycle (21 or 28 days) for other toxicities.In total, 69 patients were enrolled. No DLT or drug-related deaths occurred. Most patients (67/69; 97.1%) experienced at least one treatment-related adverse event (TRAE). Common ({greater than or equal to} 30%) TRAEs included an increase in aspartate aminotransferase, an increase in alanine aminotransferase, corneal epitheliopathy, alopecia, hypokalemia, interstitial lung disease (ILD)/pneumonitis, and an increase in aldosterone. While 34.8% of participants experienced ILD/pneumonitis, only two had a severity of grade 3. At 1.5 mg/kg Q3W, the recommended phase II dose, the objective response rate was 65.5% (19/29, 95% confidence interval [CI], 45.7-82.1), the disease control rate was 100% (95% CI, 81.2-100), and the median progression-free survival was 17.02 months (95% CI, 10.09 to not reached).ARX788 demonstrated a manageable safety profile with promising preliminary signs of activity in HER2-positive MBC patients who progressed on prior anti-HER2 therapies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
HIT_C发布了新的文献求助30
2秒前
3秒前
4秒前
kkkkk完成签到,获得积分10
4秒前
三斤完成签到 ,获得积分20
4秒前
李茵发布了新的文献求助10
5秒前
5秒前
6秒前
6秒前
wyl发布了新的文献求助10
7秒前
8秒前
8秒前
小小小值钱完成签到,获得积分20
10秒前
wangjue发布了新的文献求助10
11秒前
12秒前
12秒前
木可发布了新的文献求助10
13秒前
13秒前
wyl完成签到,获得积分10
15秒前
汉堡包应助三斤采纳,获得10
16秒前
wangqiuhong发布了新的文献求助10
18秒前
19秒前
失眠的夜梦关注了科研通微信公众号
19秒前
今后应助HIT_C采纳,获得10
20秒前
今后应助SuperZzz采纳,获得10
21秒前
ZONG发布了新的文献求助10
23秒前
Nugget发布了新的文献求助10
24秒前
李茵完成签到,获得积分10
26秒前
量子星尘发布了新的文献求助10
26秒前
汉堡包应助风趣的老太采纳,获得10
27秒前
DongWei95发布了新的文献求助30
29秒前
29秒前
29秒前
猪猪hero发布了新的文献求助10
29秒前
斯文念波发布了新的文献求助10
29秒前
31秒前
33秒前
33秒前
断数循环应助任峰采纳,获得10
34秒前
FIN应助wuyu采纳,获得30
38秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989406
求助须知:如何正确求助?哪些是违规求助? 3531522
关于积分的说明 11254187
捐赠科研通 3270174
什么是DOI,文献DOI怎么找? 1804901
邀请新用户注册赠送积分活动 882105
科研通“疑难数据库(出版商)”最低求助积分说明 809174